244 related articles for article (PubMed ID: 11603412)
1. Eptifibatide and tirofiban: new preparations. Limited benefit.
Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
[TBL] [Abstract][Full Text] [Related]
2. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
3. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
4. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
Hamm C
Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
[TBL] [Abstract][Full Text] [Related]
5. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
7. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
[TBL] [Abstract][Full Text] [Related]
8. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
9. The role of tirofiban in acute coronary syndromes.
Gomma A; Collinson J; Purcell H; Flather M
Int J Clin Pract; 2000 Mar; 54(2):121-4. PubMed ID: 10824369
[TBL] [Abstract][Full Text] [Related]
10. Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit.
Prescrire Int; 2000 Apr; 9(46):36-8. PubMed ID: 11503782
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
Brown DL; Fann CS; Chang CJ
Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
Morrow DA; Sabatine MS; Antman EM; Cannon CP; Braunwald E; Theroux P
Am J Cardiol; 2004 Sep; 94(6):774-6. PubMed ID: 15374786
[TBL] [Abstract][Full Text] [Related]
13. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
[TBL] [Abstract][Full Text] [Related]
14. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
15. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
16. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Goa KL; Noble S
Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
[TBL] [Abstract][Full Text] [Related]
17. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Marmur JD; Poludasu S; Lazar J; Cavusoglu E
Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
[TBL] [Abstract][Full Text] [Related]
18. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
Szucs TD; Meyer BJ; Kiowski W
Eur Heart J; 1999 Sep; 20(17):1253-60. PubMed ID: 10454977
[TBL] [Abstract][Full Text] [Related]
19. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Dorsch MP; Montague D; Rodgers JE; Patterson C
Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
[TBL] [Abstract][Full Text] [Related]
20. Tirofiban. A review of its use in acute coronary syndromes.
McClellan KJ; Goa KL
Drugs; 1998 Dec; 56(6):1067-80. PubMed ID: 9878994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
